7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,645.79

+634.56

+0.82%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

Antengene Corporation Limited (6996.HK)

2.790 -0.035 (-1.24%)

At close: October 30 at 4:08:06 PM GMT+8

Loading Chart for 6996.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Mobilize your Website

View Site in Mobile | Classic

Share by: